Documentos para Download:

• PDF Hipogonadismo Masculino Tardio Ou Deficiência Androgênica Do Envelhecimento Masculino (DAEM) Diagnóstico
• DIR 2019 Guidelines on Diabetes, Pre-Diabetes and Cardiovascular Diseases developed in collaboration with the EASD
• DIR Acetato de lanreotida — Sintomas associados a tumores endócrinos gastroenteropancreáticos funcionais
• DIR Acetato de octreotida de liberação prolongada — Sintomas associados a tumores endócrinos gastroenteropancreáticos funcionais
• DIR Ácido zoledrônico — Pacientes com osteoporose com intolerância ou dificuldades de deglutição dos bisfosfonatos orais
• DIR Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update
• DIR Adrenal insufficiency: identification and management
• DIR Adrenal insufficiency: identification and management (NG243)
• DIR Aflibercepte — Edema Macular Diabético
• DIR Assessment and Management of Foot Ulcers for People with Diabetes, Second Edition
• DIR Calcitonina 50 UI e 100 UI — Doença de Paget e Osteoporose
• DIR Caneta para injeção de insulina humana NPH e insulina humana regular — Aplicação de insulina para tratamento de Diabetes Mellitus
• DIR Carcinoma Diferenciado da Tireoide
• DIR CCO Thyroid Cancer Guideline: An Endorsement of the 2015 American Thyroid Association Management of the 2015 ATA Management Guideline for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer. 5-13
• DIR Chronic Complications of Diabetes Mellitus
• DIR Cipionato de hidrocortisona 10 ou 20 mg — Hiperplasia adrenal congênita
• DIR Cipionato de hidrocortisona em comprimidos de 10mg — Hiperplasia adrenal congênita
• DIR Cipionato de hidrocortisona em comprimidos de 20mg — Hiperplasia adrenal congênita
• DIR Clinical Practice Guideline: Improving Voice Outcomes after Thyroid Surgery
• DIR Clinical practice guideline for diabetes mellitus type 1
• DIR Clinical Practice Guideline for Multicomponent Behavioral Treatment of Obesity and Overweight in Children and Adolescents: Current State of the Evidence and Research Needs
• DIR Clinical Practice Guideline of Korean Medicine for Obesity
• DIR Congress of Neurological Surgeons Systematic Review and Evidence-based Guidelines for Perioperative Spine: Preoperative Osteoporosis Assessment
• DIR CONGRESS OF NEUROLOGICAL SURGEONS SYSTEMATIC REVIEW AND EVIDENCE-BASED GUIDELINES FOR THE ROLE OF SURGERY FOR PATIENTS WITH FUNCTIONING PITUITARY ADENOMAS
• DIR CONGRESS OF NEUROLOGICAL SURGEONS SYSTEMATIC REVIEW AND EVIDENCE-BASED GUIDELINES ON THE ROLE OF RADIOSURGERY FOR PATIENTS WITH FUNCTIONING PITUITARY ADENOMAS
• DIR Dapagliflozina — Diabetes Mellitus tipo 2
• DIR Denosumabe — Tratamento de osteoporose e doença renal crônica em estágio 4 e 5
• DIR Denosumabe — Tratamento indivíduos com osteoporose grave e falha terapêutica aos medicamentos disponíveis no Sistema Único de Saúde
• DIR Desmopressina oral — Diabetes Insípido central
• DIR Diabete Melito Tipo 1
• DIR Diabete Melito Tipo 2
• DIR Diabetes (type 1 and type 2) in children and young people: diagnosis and management
• DIR Diabetes in children and young people
• DIR Diabetes in pregnancy
• DIR Diabetes Insípido
• DIR Diabetes Mellitus (DM) Type 1 and 2. Evidence-based Nutrition Practice Guideline
• DIR Diabetes mellitus in pregnancy
• DIR ​Diabetes mellitus in special situations
• DIR Diabetic foot problems: prevention and management
• DIR Diabetic foot ulcers: Prevention, assessment and management
• DIR Diabetic retinopathy: management and monitoring
• DIR Diabetic retinopathy: management and monitoring (NG242)
• DIR Diagnosis of gestational diabetes mellitus: evaluation of the new IADPSG criteria
• DIR Educational interventions to promote oral hypoglycaemic adherence in adults with Type 2 diabetes (Best Practice 15(11))
• DIR Effectiveness of parent-centred interventions for the prevention and treatment of childhood overweight and obesity in community settings (Best Practice 18(3))
• DIR Empagliflozina — Diabetes Mellitus tipo 2
• DIR Finerenona — Doença renal crônica estágios 3 e 4 com albuminúria associada ao diabetes tipo 2
• DIR Foot assessment in people with diabetes mellitus
• DIR Fórmula metabólica isenta de metionina — Homocistinúria clássica
• DIR Gestational Diabetes Mellitus (GDM). Evidence Based Nutrition Practice Guideline
• DIR Gestational diabetes mellitus an update on screening, diagnosis, and follow-up
• DIR Hemoglobin A1c Targets for Glycemic Control With Pharmacologic Therapy for Nonpregnant Adults With Type 2 Diabetes Mellitus: A Guidance Statement Update From the American College of Physicians
• DIR Hiperplasia adrenal congênita
• DIR Implante biodegradável de dexametasona — Edema macular diabético em maiores de 18 anos.
• DIR Implante biodegradável de dexametasona — Edema macular diabético em pacientes não responsivos à terapia prévia com anti-VEGF
• DIR INCIDENCE OF DIABETIC RETINOPATHY BASED ON A SCREENING PROGRAMME USING A NON MYDRIATIC RETINAL CAMERA ON DIABETIC PATIENTS IN THE AUTONOMOUS COMMUNITY OF THE BASQUE COUNTRY
• DIR INESSS- Treatment of Obesity in Children and Adolescents in Primary and Secondary Care Settings
• DIR Infusão contínua de insulina — Diabetes Mellitus tipo 1
• DIR Initiating basal insulin in type 2 diabetes mellitus
• DIR Insuficiência Adrenal
• DIR Insulina análogas de ação rápida — Diabetes Mellitus tipo 2.
• DIR Insulinas análogas — Diabetes Mellitus tipo 1
• DIR Insulinas análogas — Diabetes Mellitus tipo 2
• DIR Insulinas análogas de ação prolongada — Diabetes Mellitus tipo 1
• DIR Insulinas análogas de ação prolongada — Diabetes Mellitus tipo 1
• DIR Insulinas análogas de ação prolongada — Diabetes Mellitus tipo 2
• DIR Insulinas análogas de ação prolongada — Diabetes Mellitus tipo 2.
• DIR Insulinas análogas de ação rápida — Diabetes Mellitus tipo 1
• DIR International evidence-based guideline for the assessment and management of polycystic ovary syndrome 2018
• DIR International Evidence-based Guideline for the Assessment and Management of Polyendocrine Metabolic Ovarian Syndrome (PMOS) 2028
• DIR Iodoterapia de baixas doses (30mCi e 50mCi) em regime ambulatorial — Carcinoma diferenciado da tireoide, classificados como de baixo risco ou de risco intermediário
• DIR Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline
• DIR Liraglutida — Obesidade e Diabetes Mellitus tipo 2
• DIR Liraglutida 3 mg — Obesidade e IMC acima de 35 kg/m², pré-diabetes e alto risco de doença cardiovascular
• DIR Management of asymptomatic hypoglycaemia in healthy term neonates for nurses and midwives (Best Practice 10(1))
• DIR Management of diabetes (SIGN CPG 116)
• DIR Management of Diabetes in Pregnancy
• DIR Management of diabetes in pregnancy (SIGN CPG 171)
• DIR Management of Diabetic Foot (Second Edition)
• DIR Management of Diabetic Nephropathy
• DIR Management of Hyperglycemia in Hospitalized Adult Patients in Non-Critical Care Settings: An Endocrine Society Clinical Practice Guideline
• DIR Management of Obesity
• DIR Management of Osteoporosis (Third Edition)
• DIR Management of osteoporosis and the prevention of fragility fractures (SIGN CPG 142)
• DIR Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline
• DIR Management of Thyroid Disorder
• DIR Management of Type 1 Diabetes Mellitus in Children & Adolescents
• DIR Management of Type 2 Diabetes Mellitus (5th edition)
• DIR Managing pre-diabetes a growing health concern
• DIR Metabolic dysfunction-associated steatotic liver disease (MASLD): assessment and management
• DIR Newer Pharmacologic Treatments in Adults with Type 2 Diabetes: A Clinical Guideline From the American College of Physicians
• DIR Obesity - working with local communities (PH42)
• DIR Obesity: identification, assessment and management (CG189)
• DIR ​Obesity in adults
• DIR Obesity Prevention (CG43)
• DIR Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s
• DIR Optimising glycaemic control in people with type 1 diabetes (SIGN CPG 170)
• DIR Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline Update from the American College of Physicians
• DIR Orlistate — Redução de peso em indivíduos com sobrepeso ou obesidade
• DIR Osteoporose
• DIR Osteoporose — Osteoporose
• DIR Osteoporosis
• DIR Osteoporosis: assessing the risk of fragility fracture (CG146)
• DIR Osteoporosis: risk assessment
• DIR Osteoporosis identification and management in primary care
• DIR Overweight and obesity management
• DIR Overweight and obesity management
• DIR Oxigenoterapia hiperbárica — Pé diabético
• DIR Pamidronato 30 mg — Osteoporose
• DIR Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update
• DIR Pharmacologic Treatment of Primary Osteoporosis or Low Bone Mass to Prevent Fractures in Adults: A Living Clinical Guideline From the American College of Physicians
• DIR Pharmacologic Treatments With Lifestyle Modifications in Nonpregnant Adults with Overweight or Obesity in Outpatient Settings: A Living Clinical Guideline From the American College of Physicians (April 2026)
• DIR Physical Therapist Management of Patients With Suspected or Confirmed Osteoporosis A Clinical Practice Guideline From the Academy of Geriatric Physical Therapy
• DIR Point-of-care testing de hemoglobina glicada — Pacientes diabéticos
• DIR Prevention, Identification and Management of Foot Complications in Diabetes: Technical Report
• DIR Prevention and remission of type 2 diabetes (SIGN CPG 172)
• DIR PREVENTION OF DIABETES MELLITUS TYPE 2 IN PRIMARY HEALTH CARE THROUGH HEALTHY LIFESTYLES: CARE AND RECOMMENDED CLINICAL INTERVENTION
• DIR Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline
• DIR Primary Prevention of ASCVD and T2DM in Patients at Metabolic Risk: An Endocrine Society* Clinical Practice Guideline
• DIR Primary Prevention of Childhood Obesity (Second Edition)
• DIR Protocol for Development of American Association of Clinical Endocrinology Clinical Practice Guidelines and Consensus Statements: Summary of Methodology, Process, and Policy – 2023 Update
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Diabete Insípido
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Diabete Insípido
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Diabete Melito Tipo 2
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Diabetes Mellitus tipo 1
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Diabetes Mellitus tipo 2
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Diabetes Mellitus Tipo 2
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Diabetes Mellitus tipo I
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Insuficiência Adrenal
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Osteoporose
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Osteoporose
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Retinopatia Diabética
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Sobrepeso e Obesidade em Adultos
• DIR Ranelato de estrôncio — Osteoporose
• DIR Ranibizumabe — Edema Macular Diabético (EMD)
• DIR Recommandations pour la prévention du gain pondéral et l’utilisation d’interventions comportementales et pharmacologiques dans la gestion du surpoids et de l’obésité chez les adultes en soins primaires
• DIR Recommandation sur le dépistage de la dysfonction thyroïdienne en soins primaires chez l’adulte
• DIR Recommendations for growth monitoring, and prevention and management of overweight and obesity in children and youth in primary care
• DIR Recommendations on screening for type 2 diabetes in adults
• DIR Reducing Foot Complications for People with Diabetes
• DIR Retinopatia Diabética
• DIR Risedronato 5 mg — Osteoporose
• DIR Romosozumabe e a teriparatida — para homens com osteoporose grave e falha terapêutica aos medicamentos disponíveis no SUS
• DIR Romosozumabe e reavaliação da teriparatida — Osteoporose grave
• DIR Screening of Diabetic Retinopathy
• DIR Semaglutida — Obesidade graus II e III, sem diabetes, com idade a partir de 45 anos e com doença cardiovascular estabelecida
• DIR Sibutramina — Obesidade
• DIR Sistema flash — Monitoramento da glicose em pacientes com Diabetes Mellitus tipo 1 e 2
• DIR Sobrepeso e Obesidade em Adultos
• DIR Surgical treatment of the morbid obesity
• DIR Teriparatida — Tratamento indivíduos com osteoporose grave e falha terapêutica aos medicamentos disponíveis no Sistema Único de Saúde
• DIR THE DIAGNOSIS & MANAGEMENT OF DIABETES IN CHILDREN AND ADOLESCENTS
• DIR THE DIAGNOSIS & MANAGEMENT OF DIABETES IN PREGNANCY
• DIR THE DIAGNOSIS & MANAGEMENT OF TYPE 1 DIABETES IN ADULTS & THE ELDERLY
• DIR THE DIAGNOSIS & MANAGEMENT OF TYPE 2 DIABETES MELLITUS IN ADULTS & THE ELDERLY
• DIR The effectiveness of nurse-led care in general practice on clinical outcomes in adults with type 2 diabetes (Best Practice 16(1))
• DIR The experiences of, and meaning for, women living and coping with type 2 diabetes (Best Practice 16(10))
• DIR Thyroid cancer: assessment and management
• DIR Thyroid disease: assessment and management
• DIR Transplante de membrana amniótica — Feridas crônicas e do pé diabético
• DIR Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline
• DIR Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians
• DIR TSH recombinante — Diagnóstico de carcinoma diferenciado de tireoide com indicação de iodo radioativo e contraindicação à indução de hipotireoidismo endógeno ou incapacidade de produção do TSH endógeno
• DIR Type 1 diabetes in adults
• DIR Type 1 diabetes in adults: diagnosis and management
• DIR Type 2 diabetes: prevention in people at high risk (PH38)
• DIR Type 2 diabetes in adults
• DIR Type 2 diabetes in adults: management
• DIR Type 2 diabetes mellitus personalising management with non-insulin medications
• DIR Type 2 diabetes prevention: population and community-level interventions (PH35)
• DIR Updating the Canadian Clinical Practice Guideline for Managing Pediatric Obesity: A Protocol
• DIR Usefulness of dietary treatments in Lysine metabolic disorders
• DIR Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update
• DIR Women's Experience of Diabetes Management in Pregnancy (Best Practice 18(7))

Documentos para Download:

• PDF Cesariana na inserção baixa de placenta
• PDF Cesariana e recém-nascido pequeno para a idade gestacional
• PDF Cesariana a pedido
• PDF Via de parto na gestação gemelar
• PDF Via de parto em caso de cesariana em gestação anterior
• DIR Acetato de noretisterona (10 mg) e o dienogeste — Endometriose
• DIR Ácido acetilsalicílico — Prevenção de pré-eclâmpsia e eclâmpsia em gestantes de alto risco
• DIR Antenatal, Intrapartum and Postnatal Care in Low Risk Pregnancy
• DIR Antenatal and postnatal mental health
• DIR Antenatal and postnatal mental health: clinical management and service guidance
• DIR Antenatal care
• DIR Antenatal care
• DIR Assessment of Adult Women with Ovarian Masses and Treatment of Epithelial Ovarian Cancer: ASCO Resource-Stratified Guideline
• DIR Atenção à Gestante a operação cesariana - Diretriz
• DIR Australian Pregnancy Care Guidelines 2018 Edition
• DIR Caesarean birth
• DIR Caesarean birth
• DIR Children and young people exposed prenatally to alcohol (SIGN CPG 156)
• DIR Clinical Practice Guideline of Korean Medicine for Female Infertility
• DIR Clinical Practice Guideline of Korean Medicine for Nausea and Vomiting for Pregnancy
• DIR Contraception
• DIR Contraceptive services for under 25s (PH51)
• DIR Detecção pré-natal de infecção pelo vírus T-linfotrópico humano (HTLV) 1/2 — Triagem e confirmação do diagnóstico de HTLV 1/2 em gestantes no pré-natal
• DIR Diabetes in pregnancy: management from preconception to the postnatal period
• DIR Diretrizes Diagnósticas e Terapêuticas — Neoplasia Maligna Epitelial de Ovário
• DIR Dispositivo intrauterino liberador de levonorgestrel — Endometriose com contraindicação ou não adesão aos contraceptivos orais combinados (COCs)
• DIR Dolutegravir — Gestantes vivendo com HIV
• DIR Dosagem do antígeno CA125 — Acompanhamento de tratamento e seguimento pós-tratamento de neoplasia maligna epitelial de ovário
• DIR Ectopic (extrauterine) pregnancy
• DIR Ectopic pregnancy and miscarriage
• DIR Ectopic pregnancy and miscarriage: diagnosis and initial management
• DIR Endometriose
• DIR Endometriosis
• DIR Endometriosis: diagnosis and management
• DIR Enoxaparina — Gestantes com trombofilia
• DIR Everolimo — Câncer de mama avançado na pós-menopausa
• DIR Exames diagnósticos — Trombofilia em gestantes
• DIR Fertility problems
• DIR Fertility problems: assessment and treatment (CG156)
• DIR Fetal monitoring in labour
• DIR Guía de Práctica Clínica sobre el manejo de la anticoncepción intrauterina y hormonal
• DIR Guidelines for the management of pregnant and breastfeeding women in the context of Ebola virus disease
• DIR Heavy menstrual bleeding
• DIR Heavy menstrual bleeding: assessment and management
• DIR Heparina de baixo peso molecular — Gestantes e puérperas com trombofilia
• DIR Hormone Therapy during Menopause in Malaysia Women
• DIR Implante subdérmico de etonogestrel — Anticoncepção em mulheres de 15 a 19 anos de idade
• DIR Inducing labour
• DIR Inducing labour
• DIR Interventions to Assist Perioperative Temperature Management for Women Undergoing Cesarean Section (Best Practice 17(1))
• DIR Intrapartum care
• DIR Intrapartum care
• DIR Intrapartum care: existing medical conditions and obstetric complications
• DIR Intrapartum care for healthy women and babies (CG190)
• DIR Intrapartum care for women with existing medical conditions or obstetric complications and their babies
• DIR Long-acting reversible contraception
• DIR Management of epithelial ovarian cancer (SIGN CPG 135)
• DIR Management of Postnatal Corticosteroids for the Prevention of Chronic Lung Disease In Preterm Infants
• DIR Management of stage I ovarian cancer 4-13v3
• DIR Menopause
• DIR Menopause: identification and management
• DIR Multiple pregnancy: twin and triplet pregnancies
• DIR Neoplasia Maligna Epitelial de Ovário (DDT)
• DIR Olaparibe — Câncer de ovário (incluindo trompas de Falópio ou peritoneal primário), seroso ou endometrioide, recém diagnosticado, de alto grau, avançado (estágio FIGO III ou IV), com mutação nos genes BRCA, sensível à quimioterapia de primeira linha, à ba
• DIR Oncogenetic testing and follow-up for women with familial breast/ovarian cancer, Li Fraumeni syndrome and Cowden syndrome
• DIR Organizational Guideline for Gynecologic Oncology Services in Ontario
• DIR Ovarian cancer
• DIR Ovarian cancer : diagnosis, treatment and follow-up
• DIR Ovarian cancer: recognition and initial management
• DIR Ovarian carcinoma
• DIR Palivizumabe — Prevenção da infecção pelo vírus sincicial respiratório em crianças prematuras com idade gestacional de 29 a 31 semanas e seis dias
• DIR PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline
• DIR PARP Inhibitors in the Management of Ovarian Cancer: Rapid Recommendation Update
• DIR PET Imaging in Ovarian Cancer 7
• DIR Pharmacologic Treatments for Females With Menopausal Vasomotor Symptoms: A Clinical Guideline From the American College of Physicians
• DIR Postnatal care
• DIR Postnatal care
• DIR Pregnancy and complex social factors: a model for service provision for pregnant women with complex social factors
• DIR Prenatal screening for Down syndrome through fetal DNA sequencing from maternal blood
• DIR PRENATAL SCREENING OF DOWN SYNDROME
• DIR Preterm labour and birth
• DIR Preterm labour and birth
• DIR Progestágenos orais — Endometriose
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Endometriose
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Síndrome dos Ovários Policísticos
• DIR Recommandations concernant le dépistage de la bactériurie asymptomatique durant la grossesse
• DIR Recommandation sur l’utilisation d’instruments de dépistage de la dépression durant la grossesse et la période postnatale
• DIR SEROPREVALENCE OF TRYPANOSOMA CRUZI INFECTION IN LATIN AMERICAN WOMEN OF FERTILE AGE AND DURING PREGNANCY IN THE AUTONOMOUS COMMUNITY OF THE BASQUE COUNTRY
• DIR Síndrome de Ovários Policísticos
• DIR Sistema intrauterino liberador de levonorgestrel 52 mg — Anticoncepção em mulheres de 15 a 19 anos de idade
• DIR Systemic Therapy for Recurrent Epithelial Ovarian Cancer 4-3v4
• DIR THE MANAGEMENT OF INFERTILITY
• DIR Twin and triplet pregnancy
• DIR Use of Race in Prenatal Screening
• DIR Weight management before, during and after pregnancy (PH27)
• DIR What are the recommended clinical assessment and screening tests during pregnancy?
• DIR WHO antenatal care recommendations for a positive pregnancy experience. Maternal and fetal assessment update
• DIR WHO antenatal care recommendations for a positive pregnancy experience. Nutritional interventions update
• DIR WHO antenatal care recommendations for a positive pregnancy experience. Nutritional interventions update
• DIR WHO antenatal care recommendations for a positive pregnancy experience. Nutritional interventions update
• DIR WHO guideline on preventing early pregnancy and poor reproductive outcomes among adolescents in low- and middle-income countries
• DIR WHO recommendation on advance misoprostol distribution to pregnant women for prevention of postpartum haemorrhage
• DIR WHO recommendation on calcium supplementation before pregnancy for the prevention of pre-eclampsia and its complications
• DIR WHO recommendation on screening of pregnant women for intrapartum antibiotic prophylaxis for the prevention of early onset Group B streptococcus disease in newborns
• DIR WHO recommendation on uterine balloon tamponade for the treatment of postpartum haemorrhage
• DIR WHO recommendation on vaginal preparation with antiseptic agents for women undergoing caesarean section
• DIR WHO recommendations on antenatal corticosteroids for improving preterm birth outcomes
• DIR WHO recommendations on antiplatelet agents for the prevention of pre-eclampsia
• DIR WHO recommendations on induction of labour, at or beyond term
• DIR WHO recommendations on mechanical methods for induction of labour
• DIR WHO recommendations on outpatient settings for induction of labour
• DIR WHO recommendations on the management of sickle cell disease during pregnancy, childbirth and the interpregnancy period